Antiretroviral therapy and TB

Area of Science:

• Infectious Diseases
• Public Health
• Clinical Medicine

Background:

• The global convergence of Human Immunodeficiency Virus (HIV) and Tuberculosis (TB) epidemics necessitates effective management strategies for co-infected patients.
• Clinicians face challenges due to overlapping and additive toxicities between HIV and TB medications.

Purpose of the Study:

• To outline the clinical complexities in managing patients co-infected with HIV and TB.
• To highlight key challenges including antiretroviral therapy selection, initiation timing, and immune reconstitution disease management.

Main Methods:

• This abstract summarizes clinical considerations for managing HIV-TB co-infection.
• It reviews potential drug interactions and therapeutic complexities.

Main Results:

• Co-infection presents significant therapeutic challenges, including managing drug toxicities and optimizing treatment sequencing.
• Specific challenges involve selecting first- and second-line antiretroviral therapy, determining optimal antiretroviral initiation timing, and addressing immune reconstitution inflammatory syndrome (IRIS).
• TB diagnosis after initiating HIV therapy adds further complexity.

Conclusions:

• Despite the complexities, integrated care programs demonstrate success in treating patients with both HIV and TB.
• Effective management relies on understanding and mitigating overlapping toxicities and addressing specific clinical challenges.